Progress in PrEP Uptake

As we look back on 2023, powerful crosscurrents confront HIV prevention and global health equity. More options than ever before could be available, but many forces threaten to undermine access to proven prevention options that exist today and the development of additional options that are still needed. Threats to PEPFAR and hate laws targeting LBGTQI+ people are just a sample.

Upstream research and development is dynamic, but robust stakeholder engagement and sustainable funding must still be secured and integrated into a people-centered research agenda. These commitments are the compass that will ultimately lead to impact in the real world. The highlights below provide a snapshot of key updates in Q3 of 2023 and resources to inform advocacy on these critical questions.

Progress in PrEP Uptake

These updates from AVAC’s Global PrEP Tracker explore trends in 2023 and highlight new data as of September 2023.

PEPFAR and PrEP

PEPFAR’s role has been instrumental to accelerating global uptake of PrEP to date. This year, four countries started providing PrEP for the first time, and seven countries exceeded 70,000 new PrEP initiations, most of which are attributable to PEPFAR. This lifesaving, uniquely effective, program must see continued full funding and a 5-year reauthorization to carry on this work and help to put the world on track to control the epidemic.

PEPFAR Support for PrEP in 2023

47 PEPFAR-Supported Countries overall

6 Countries where PEPFAR reported more than 100,000 new initiations

4 Countries where PEPFAR reported first PrEP initiations
Cumulative PrEP Initiation Milestones

**Global Milestones**
- The world surpassed 5.6 million cumulative PrEP initiations as of September 2023. Initiations increased by 700,000+ since Q2 2023. Though comparable to previous quarterly increases, it is the highest ever recorded quarterly increase by the Global PrEP Tracker.
- At the same time last year the world had reached 3.3 million cumulative PrEP initiations, representing a doubling of initiations since then.

**Country Level Milestones**
- Early adopting African countries continue to show the most rapid increases in PrEP uptake. South Africa has shattered 1 million cumulative initiations. Nigeria, Uganda, and Zambia have all surpassed 500,000 initiations. Kenya has surpassed 400,000, and Zimbabwe has surpassed 200,000.
- Malawi and Brazil saw jumps of approximately 20,000 initiations over this quarter, while Lesotho had more modest increases of 10,000 initiations.
- Dozens of countries continue to grow their programs. For example, El Salvador, Honduras, and South Sudan all surpassed 1,000 cumulative initiations.
- Cyprus and Malta recorded their first oral PrEP initiations, at 29 and 579 respectively.

Spotlight on West Africa

As of Q3 2023, the top five West and Central African countries for PrEP initiation have surpassed 10,000 initiations; Cameroon, Côte d’Ivoire, Democratic Republic of the Congo (DRC), Ghana, and Nigeria. Nigeria has marked almost 550,000 cumulative initiations as of this quarter, ranking it second, behind South Africa, worldwide. These milestones can be credited to targeted PEPFAR investments. But despite these successes, West and Central Africa make up only 14% of PrEP initiations recorded in Africa, compared to 85% reported by East and Southern Africa. These same countries are home to two thirds of all people living with HIV in West Africa. There is vital work to be done to close the gap.

West and Central Africa can and must continue to leverage this recent growth in oral PrEP by making additional HIV prevention options available. In September, Nigeria’s regulators approved injectable cabotegravir (CAB for PrEP)—approving the first new biomedical HIV prevention option in a West and Central African country since oral PrEP. But at this time, only one other CAB for PrEP application has been submitted in the region, in Côte d’Ivoire, and none for the dapivirine vaginal ring (DVR). Only one CAB for PrEP implementation study is planned for the region.
Current HIV prevention options aren’t reaching all who need them. Access to a range of options that meet the needs of diverse people, especially those most at risk, will be essential to meeting global targets for ending the HIV epidemic.

**CAB for PrEP Supply:** In October 2023, ViiV, the developer and sole manufacturer of CAB for PrEP for now, announced a 40% increase in forecasted doses that could be available for non-commercial use in low- and middle-income countries through 2025, an increase to 1.2 million potential doses. Of these, 116,000 have been allocated to post-trial access for HPTN 083 and 084 participants; 129,000 for an initial set of eight implementation studies; 326,000 to PEPFAR programs in Malawi, Ukraine, Vietnam, Zambia, and Zimbabwe; leaving at least 629,000 doses available for procurement by PEPFAR, Global Fund and national governments. See more details in our Country Planning Matrix. Three generic manufacturers are currently engaged in technology transfer, with potential doses from them beginning in 2026 or 2027.

**Implementation Science (IS):** As DVR and CAB for PrEP supplies arrive in countries, dozens of implementation science studies are underway in 22 different countries. Check out AVAC’s Integrated Study for more details and stay tuned for updates.

**PrEParing for Choice:** For the first time since oral PrEP was introduced in 2012, PrEP users will have a range of methods to choose from—but only if they have access to them. Policy makers, donors, governments, and implementers must commit to making these methods available, accessible, and affordable. The HIV Prevention Choice Manifesto, launched in September by the African Women’s HIV Prevention Community Accountability Board, outlines what needs to happen to make choice a reality.

**Approval Information**

Malaysia, Nigeria, Peru, Zambia and the European Medicines Agency approved CAB for PrEP. ViiV also made submissions in Canada, Columbia and the UK. There are now 13 regulatory approvals and 15 additional submissions that are pending.
The HIV prevention pipeline has evolved: Few products are in late stage or efficacy trials, newly proven products are rolling out, and early phase clinical trials are exploring innovative strategies. R&D is focused on ARV and non-ARV based prevention products and HIV vaccines that build on new knowledge about the virus. The late-stage trials of recent years and basic science have brought deepening insights that are being applied today to a diversity of ‘upstream’ interventions.

**MK-8527 Announced:** Merck announced a new Phase 2a trial to evaluate the safety, tolerability, and pharmacokinetics of a monthly oral pill, MK-8527. The trial began in November 2023 in participants at low-risk for HIV acquisition. If successful, Phase 3 trials could start in 2025.

**Purpose Program:** A new Phase 2 study, PURPOSE 5, will evaluate lenacapavir as a twice-yearly prevention option in France and the United Kingdom, as part of the larger PURPOSE program. Purpose 5 is recruiting participants who are disproportionately affected and often underrepresented in HIV clinical trials. PURPOSE 1 and 2 are Phase 3 efficacy studies in Argentina, Brazil, Mexico, South Africa, Thailand, Uganda and the United States. PURPOSE 3 & 4 are smaller studies focused on populations facing disproportionate risk.

**The Dual Prevention Pill (DPP):** In September, the DPP, which would protect against pregnancy and HIV, moved to the next stage in R&D. A pilot bioequivalence study has shown the pill’s combined drugs— an antiretroviral and a contraceptive— are absorbed at an equivalent rate as taking them separately. The DPP now moves to a larger bioequivalence study needed for a regulatory submission. Check out the updated DPP Market Preparation and Introduction Strategy for highlights. The Population Council and Medicines360 are also developing a second-generation DPP with F/TAF.

### Table: Prevention Products

<table>
<thead>
<tr>
<th>Prevention Product</th>
<th>2022</th>
<th>2023</th>
<th>2024</th>
<th>2025</th>
<th>2026</th>
<th>2027</th>
<th>2028</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Q1</td>
<td>Q2</td>
<td>Q3</td>
<td>Q4</td>
<td>Q1</td>
<td>Q2</td>
<td>Q3</td>
</tr>
<tr>
<td>Vaginal Ring</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dapivirine</td>
<td>Monthly</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Long-Acting Injectables</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cabotegravir</td>
<td>One intramuscular injection</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(3ml) every 2 months</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lenacapavir</td>
<td>Two subcutaneous injections</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(1.5ml each) every 6 months</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral PrEP</td>
<td>Daily</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MK-8527</td>
<td>Monthly</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dual Prevention Pill</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Co-formulated TDF/FTC and ethinyl estradiol/levonorgestrel oral contraceptive pill</td>
<td>Daily</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Note:</strong> Demonstrated modest efficacy • Unclear demand &amp; limited initial supply • Initial price ~$180 per year • Oct 2023: PopCouncil licensed Kiara Health in SA to mfg.; volumes and prices unknown • Opportunity to build market and platforms for vaginal rings</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Note:</strong> Demonstrated high efficacy • Unclear demand &amp; limited initial supply • Initial LMC price ~$240/yr; in 2024 ~$170/yr • March 2023: MPP &amp; ViiV licensed to 3 generics that need 7 years to market • Opportunity to build market and platforms for injectables</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Note:</strong> Possible product introduction • Possible Phase 3 Go/No-Go Decision for Phase 3 in Q1 2025</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Note:</strong> Pilot bioequivalence (BE) study • Pivotal BE • Possible regulatory approvals • Possible product introduction</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| **Note:** Acceptability Study: HPTN 104
Prevention Playlist

The most effective advocacy is based on smart analysis and accurate information. AVAC develops a wide range of materials and resources to inform decision making and action. Check out these essential resources to the global conversation on HIV prevention and global health equity.

JOIN

ICI AIDS: The biennial International Conference on AIDS and Sexually Transmitted Infections in Africa. Dec 4-9. Register
How Our Environment Impacts Cure, webinar, Dec 13. Register
Sex, Gender & HIV Cure Research, Dec 6. Register

READ

Progress Against HIV and AIDS is Fragile, article
STI Watch Newsletter, a curated resource on the latest STI vaccines, diagnostics and other prevention strategies.
The STI Clinical Trials Dashboard, tracking trials on vaccines, doxycycline as post-exposure prophylaxis (DoxyPEP) and diagnostics against chlamydia, gonorrhea, hepatitis B, herpes simplex virus (HSV), human papillomavirus, syphilis and trichomoniasis infections.
Paving the Road for STI Prevention Advocacy, blog
Three HLMs, A Host of Challenges and One Major Victory, blog
A Legacy of Impact: The power and reach of AVAC’s Fellows, report
Advancing Choice in HIV Prevention research, blog
Adherence, Safety and Choice, Lancet article on MTN 034 offering DVR and oral PrEP to African women.
How ‘unauthorized status’ is threatening US global HIV initiative, article
The GPP Body of Evidence, online clearinghouse
From The Lab to The Jab, issue briefs
Bending the curve: What a decade-long rollout-out of the anti-HIV pill can teach the world, article

WATCH AND LISTEN

The anti-HIV Jab is Coming to SA. Find Out When and How, podcast
Spotlight on new PrEP tools & data, from R&D to access, webinar
Africa Health R&D Week, webinar series
Pandemic Accord Briefing for Civil Society, webinar
PrEP Resources Showcase, workshop
Let’s Talk HIV Research: An introduction to the science under investigation, webinar
HPTN 096: Building Equity Through Advocacy—An integrated status-neutral approach for ending the epidemic among Black gay men in the South, webinar
Inclusion of Pregnant and Lactating People in HIV Research: What you need to know, podcast
Results from STI Landscaping Analyses in East and Southern Africa—Part 1 & Part 2, webinar
Pioneering Self-care Solutions to Drive Access to HIV Prevention and Family Planning, webinar
Boo, Syphilis is Really Back!, webinar
Practicality over Panic: What happens if PEPFAR isn’t reauthorized?, webinar
Foundations of HIV Cure Research, webinar
PEPFAR at 20: Keeping the promise, podcast

About AVAC

AVAC is an international non-profit organization that leverages its independent voice and global partnerships to accelerate ethical development and equitable delivery of effective HIV prevention options, as part of a comprehensive and integrated pathway to global health equity. Follow AVAC on Twitter @HIVpxresearch; find more at www.avac.org, www.prepwatch.org and www.stiwatch.org.